NLA Resources
Knowledge Center
Membership Resources
Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.
After making your filter selections, please scroll down to see results.
Top Line Results from the Phase 3 Lp(a)HORIZON Trial
On September 4, 2026, Novartis announced the topline results of its phase 3 Lp(a)HORIZON trial. Novartis shared that while pelacarsen lowered lipoprotein(a) [Lp(a)] levels, the…
Make Your Voice Heard: Support LDL-C Quality Measurement in the CMS CY 2027 Physician Fee Schedule
The Centers for Medicare & Medicaid Services (CMS) is accepting public comments on the Calendar Year (CY) 2027 Medicare Physician Fee Schedule Proposed Rule, and…
National Lipid Association Highlights New Meta-Analysis Supporting LDL-C Lowering in Primary Prevention
The National Lipid Association (NLA) today announced the publication of a new meta-analysis evaluating the impact of low-density lipoprotein cholesterol (LDL-C) lowering on major adverse…
Dietary Patterns & Nutrition Interventions for Individuals with Dyslipidemia
The mission of the National Lipid Association (NLA) is “to enhance the science and practice of lipidology and promote optimal cardiometabolic health.” The NLA leadership…
US Food and Drug Administration Approves LIB Therapeutics’ LEROCHOL™ (lerodalcibep-liga) for Adults with Elevated LDL Cholesterol
CINCINNATI, Ohio – December 15, 2025 – LIB Therapeutics Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their…
Amgen Makes Repatha® Available Through AmgenNow, A Direct-to-patient Program in the US
THOUSAND OAKS, Calif., Oct. 6, 2025 /PRNewswire/ — Amgen (NASDAQ: AMGN) today announced the launch of AmgenNow, a new direct-to-patient program starting with Repatha® (evolucumab). This follows landmark results demonstrating Repatha significantly…
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab)…
NLA and FNLA Urge CMS and Administrator Oz to Include Low-Density Lipoprotein Cholesterol (LDL-C) Measurement in CMS Quality Measurement Programs
JACKSONVILLE, Fla., May 19, 2025/PRNewswire/ — The National Lipid Association (NLA) and Foundation of the National Lipid Association (Foundation) urge the Centers for Medicare & Medicaid…